National and Kapodistrian University of Athens
Γενετική ετερογένεια του ιού της ηπατίτιδας Β: κατανομή γονοτύπων και συσχέτιση με την εξέλιξη της νόσου σε ασθενείς με χρονία λοίμωξη από τον ιό της ηπατίτιδας Β
Abstract
dc:descriptionΑBSTRACTGenetic variability of hepatitis B virus: Distribution of HBV genotypesand correlation with disease progression in patients with chronic HBVinfectionIntroduction: The role of HBV genotypes and mutations in the core promoterand/or precore region in the natural course of chronic HBV infection remainscontroversial and data from our country are limited.Aims: The aim of this cohort study was to evaluate the association of HBVgenotypes and core promoter and/or precore mutations with the clinicalphases of chronic HBV infection and the progression of liver disease.Methods: Core promoter and precore sequences were analyzed and HBVgenotype was determined with direct sequencing in 255 patients (M/F:188/67, mean age 43,5+14,3 years), 48 had HBeAg-positve chronic HBVinfection [10 HBeAg-positive with normal ALT (immune tolerance phase) and38 HBeAg-positive chronic hepatitis B (CHB)] and 207 had HBeAg-negativechronic HBV infection [147 HBeAg-negative chronic hepatitis B and 60 werechronic inactive carriers. Median follow-up was 108 (6-484) months.Results: All patients had genotype A or D. Genotype D was predominant inall groups and it was found in 95.7% of study population. Although genotype Awas found only in 4.3% of total population, it was detected more frequently(exclusively) in patients with HBeAg-positive CHB versus the others group(29% vs 0%, 0%, 0%, P<0,001). The G1896A mutation was detected in77.2% of the total population and it was found significantly more frequent inpatients with HBeAg-negative chronic HBV infection compared with patientswith HBeAg-positive chronic HBV infection (91.5% vs 10.5%, P<0,001). TheG1896A was not detected in any HBeAg-positive patient with normal ALT,was found in 13% of patients with HBeAg-positive CHB, in 90% of inactivecarriers and in 92% of patients with HBeAg-negative CHB. The mutationsA1762Tand/orG1764A were detected in 68% of study population and theirfrequency was higher, but not significantly in patients with HBeAg-negativechronic HBV infection compared with patients with HBeAg-positive chronicHBV infection (70.2% vs 55.3%, p=NS). Mutations in the basic core promoterwere detected in 28.6% of patients with HBeAg-positive with normal ALT, in61.3% of patients with HBeAg-positive CHB, in 62.7% of inactive carriers andin 73.4% of patients with HBeAg-negative CHB. The proportions of G1896Aprecore mutation and of the core promoter mutations (A1762T and/orG1764A)were similar between patients with HBeAg-negative CHB and inactive carriers(92% vs 90% and 73.4% vs 62.7% respectively, p=NS). Hepatocellularcarcinoma (HCC) developed in 33 patients during follow-up. Patients whodeveloped HCC compared to those who did not, were more frequently older,males and with HBeAg-negative rather than HBeAg-positive chronic HBVinfection. In addition, core promoter mutations were more commonly detectedin HCC than in non-HCC patients (95% vs 68%, P=0,015), while theproportion of precore mutation was similar between these two groups.During follow-up, 30/48 patients achieved HBeAg seroconversion. The rate ofHBeAg seroconversion was similar between genotype A and D, but patientswith genotype A seroconverted later (about one decade) than patients withgenotype D, with higher proportion (71%) of remission of liver disease andHBsAg loss after HBeAg seroconversion. Patients with genotype A achieveHBeAg seroconversion with the development of mutations in the BCP regionand no patient had G1896A. In patients with genotype D, the HBeAgseroconversion was achieved with the development of G1896A and althoughthe mutations in the BCP region were frequent, no association with HBeAgloss was found.Conclusions: 1. HBV genotype D is endemic in Greece and is associatedwith every phase of chronic HBV infection. The proportion of genotype A isonly 5% of chronic HBV cases overall, but it increases up to 29% in HBeAgpositiveCHB. 2. Precore mutations are detected in a minority (10%) of ourHBeAg-positive chronic HBV patients, but core promoter mutations may bepresent in up to 55% of them. However, precore and basic core promotermutations are detected in the majority of patients with HBeAg-negativechronic HBV infection (90.5% vs 79.2% respectively). 3. The prevalence ofmutations in the precore and core promoter region seems to be similarbetween patients with HBeAg-negative CHB and inactive carriers, but corepromoter mutations are significantly more frequently detected in patients whodevelop HCC. 4. The rate of HBeAg seroconversion was similar betweengenotype A and D, but patients with genotype A seroconvert later and havehigher proportion of remission of liver disease and of HBsAg loss after seroconversion.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Dimou, Evangelini
- Δήμου, Ευαγγελινή
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40621